Lucrative partnerships lately in the targeted protein degradation (TPD) space have shone an even brighter light on the already-intriguing approach, and among the firms to spark enthusiasm is Monte Rosa Therapeutics Inc., pursuing programs aimed solely at drugs that deploy molecular “glue” – an E3 ligase enzyme affixed to a target substrate.